Kidney transplant study: which drug better prevents rejection?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged from 18 to 70 years * Recipient of a deceased or living donor kidney transplant with the following criteria: * Incompatible grafts rate ≥ 50% for the last available serum before transplantation \< 3 months * Anti-HLA antibodies positive * Negative DSA by luminex method on historical serum and day serum * T and B negative Cross match on historical and day serum * Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at screening, and are required to practice an approved and reliable method of birth control for the duration of the study and for a period of 2 months after study medication discontinuation, even where there has been a history of infertility * Patients who are willing and able to participate in the full course of the study and from whom written informed consent has been obtained. * Patients affiliated to, or recipients of, a social security system Exclusion Criteria: * Recipients of a multi-organ transplantation, including dual kidneys, or who have previously received non renal transplanted organs * Recipients of a kidney from non-heart beating donor, or with ABO incompatibility against the donor or with a T positive cross match * Patients with severe uncontrolled systemic infection or severe allergy requiring acute or chronic treatment * Aspartate aminotransferase (ASAT), Alanine Amino Transferase (ALAT) or bilirubin ≥ 3 upper limit of the normal range (ULN) * Known hypersensitivity or contra-indication to rabbit proteins, basiliximab, tacrolimus, mycophenolic acid or any of the product excipients * Patients who are Hepatitis C positive (positive PCR and normal hepatic test may be included), HIV positive, or Hepatitis B surface antigen positive (AgHBs). * Patients with thrombocytopenia \< 75,000/mm3, an absolute neutrophils count \< 1,500/mm3, leukocytopenia \< 2,500/mm3, and/or hemoglobin \< 8g/dL at inclusion visit * Patients with any past or present malignancy within the last five years except excised squamous or basal cell carcinoma of the skin and treated in situ cervix uteri cancer * Any surgical or medical condition, excluding transplantation which compromise the inclusion of the patient (investigator's opinion) * Female patients who are pregnant, breast feeding or capable to become pregnant and not wishing or capable to practice a medically approved and reliable method of birth control * Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator